HOMEPRODUCTSCOMPANYCONTACTFAQResearchDictionaryPharmaSign Up FREE or Login

[The clinical efficacy of Vuglesorb enterosorbent in diabetic patients].

Abstract
Carbonic fibrous enterosorbent "Vuglesorb" used as a part of complex anti-diabetic treatment contributes to normalization of metabolism, promotes liquidation of ketoacidosis and principal morbid manifestations. Alongside with this, glycaemia and fructosamine blood level come to the norm. Marked anti-atherogenic effect was also observed. The drug is recommended for the treatment of patients with diabetes mellitus.
AuthorsP M Bodnar, V Ian'zhon', O M Prystupiuk, N I Lopushenko
JournalLikars'ka sprava (Lik Sprava) 1993 Oct-Dec Issue 10-12 Pg. 102-4 ISSN: 1019-5297 [Print] Ukraine
Vernacular TitleKlinichna efektyvnist' enterosorbenta "Vuhlesorb" u khvorykh na tsukrovyÄ­ diabet.
PMID8030290 (Publication Type: English Abstract, Journal Article)
Chemical References
  • Carbosorb
  • Powders
  • Tablets
  • Carbon
Topics
  • Carbon (administration & dosage)
  • Combined Modality Therapy
  • Diabetes Mellitus, Type 1 (blood, therapy)
  • Diabetes Mellitus, Type 2 (blood, therapy)
  • Drug Evaluation
  • Enterosorption (methods)
  • Humans
  • Powders
  • Remission Induction
  • Tablets

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research graph!


Choose Username:
Email:
Password:
Verify Password:
Enter Code Shown: